Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Susan Foden | M | 71 |
Evgen Ltd.
 Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | 13 years |
| Barry Clare | M | 71 |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | 15 years |
| Alan Barge | M | - | 9 years | |
| Charles Buck | M | 77 | 19 years | |
| Joseph Dominic Sorbara | M | - |
York University
| 36 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Bradshaw | M | 60 |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | 2 years |
| Taki Sarantakis | M | - |
York University
| 5 years |
| Ehab Mohammed Hassan Abou Eish | M | - |
The University of Nottingham
| 4 years |
| Stephen Moon | M | 67 | 8 years | |
| Marc d'Abbadie | M | - |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | 4 years |
| Fiona MacLaughlin | M | - |
The University of Nottingham
| 7 years |
| David Howat | M | 66 |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom. | 3 years |
| S. Steve Popoff | M | - |
York University
| 3 years |
| Stuart Bradley | M | - |
The University of Nottingham
| 5 years |
| Susan Clement Davies | F | 62 | 5 years | |
| Richard Moulson | M | - | - | |
| Scott Howson | M | - |
York University
| 7 years |
| Mohammed Zahir Al-Abri | M | - |
The University of Nottingham
| 8 years |
| Sing Hung Chen | M | 56 |
York University
| 6 years |
| Chris Hensen | M | - |
York University
| 5 years |
| Geoff Neil | M | - |
The University of Nottingham
| 7 years |
| Neville Bain | M | 83 | 8 years | |
| George Zornas | M | 56 |
The University of Nottingham
| 5 years |
| Michael Giordano | M | - |
York University
| 6 years |
| Terry Kawaja | M | - |
York University
| 4 years |
| Robert Ng | M | - |
York University
| 4 years |
| John Kousinioris | M | 59 |
York University
| 2 years |
| Paul Ghezzi | M | - |
York University
| 4 years |
| Anthony Goldstein | M | - |
York University
| 4 years |
| Michael S.B. Foo | M | - |
York University
| 4 years |
| Kuen Kou | F | 64 |
York University
| 4 years |
| Lisa McCorquodale | F | - |
York University
| 4 years |
| Tiffany Lathe | F | 52 |
York University
| 4 years |
| Aldo Baiocchi | M | 55 |
York University
| 4 years |
| Ka Ying Liu | M | 54 |
York University
| 4 years |
| Yu YI Zhao | F | - |
York University
| 4 years |
| Sin Nang Chiu | M | 64 |
York University
| 5 years |
| Frank Florio | M | - |
York University
| 4 years |
| Rewadee Jantamaneechote | M | 49 |
The University of Nottingham
| 3 years |
| Gabriel Patterson | M | - |
York University
| 3 years |
| Chris Coulton | M | - |
The University of Nottingham
| 3 years |
| Greg Jeffs | M | - |
York University
| 4 years |
| Sohil Mana | M | 66 |
York University
| 4 years |
| Satya Bhakti Parikesit | M | 51 |
The University of Nottingham
| 3 years |
| Igal Sudman | M | - |
York University
| 4 years |
| Peter Pekos | M | - |
York University
| 1 years |
| Kwok Leung Lo | M | 56 |
York University
| 4 years |
| Matthew Robert Stanesby | M | - |
The University of Nottingham
| 3 years |
| Joe D'Angelo | M | - |
York University
| 4 years |
| Lisa Lafave | F | - |
York University
| 3 years |
| Kai Chiu Chow | M | 59 |
York University
| 2 years |
| Man Kam Fung | M | 56 |
York University
| 4 years |
| Grant Parson | M | - |
York University
| 4 years |
| Warren Collier | M | - |
York University
| 4 years |
| Sarah Gavron | F | 54 |
York University
| 4 years |
| William Stenhouse Mitchell | M | - |
York University
| 4 years |
| Craig C. Zawada | M | 53 |
York University
| 4 years |
| Gregory Ebel | M | 60 |
York University
| 4 years |
| Ismail Husin | M | 59 |
York University
| 4 years |
| George Langdon | M | 65 |
York University
| 4 years |
| Gary Knight | M | - |
York University
| 2 years |
| Peter George Lutz | M | 63 |
The University of Nottingham
| 2 years |
| Thomas Brent Snowden | M | - |
York University
| 4 years |
| Carol Hansell | F | 66 |
York University
| 2 years |
| Ronald D. Schmeichel | M | 57 |
York University
| 4 years |
| Neil Sheehy | M | - |
York University
| 3 years |
| Jon A. Douglas | M | 61 |
York University
| 2 years |
| Shu-Yang Tan | M | 63 |
York University
| 4 years |
| Michael Horowitz | M | - |
York University
| 4 years |
| Khurram Qureshi | M | 60 |
York University
| 4 years |
| Domenico Bertucci | M | - |
York University
| 4 years |
| Paul Samuel Gardner | M | - |
York University
| 4 years |
| Christine Charette | F | - |
York University
| 2 years |
| Mark Andrew Kinney | M | - |
York University
| 4 years |
| Christopher R. Blake | M | - |
York University
| 2 years |
| Michael Cooper | M | 63 |
York University
| 2 years |
| Andrew Shatford McCreath | M | - |
York University
| 2 years |
| Woon Cheung Tung | M | 53 |
York University
| 4 years |
| Wayne J. A. Wilson | M | - |
York University
| 4 years |
| Thierry Michael di Nallo | M | - |
York University
| 4 years |
| Mario Piccone | M | - |
York University
| 4 years |
| Timothy Newington | M | - |
York University
| 4 years |
| Kin Chun Wong | M | 69 |
York University
| 4 years |
| David Parsons | M | - |
York University
| 5 years |
| Sandra Wilson | F | - |
York University
| 4 years |
| Benjamin Hecht | M | - |
York University
| 4 years |
| Victoria R. Chiappetta | F | - |
York University
| 4 years |
| Lee Goldman | M | - |
York University
| 2 years |
| Norman Ko | M | 59 |
York University
| 4 years |
| Ian Robertson | M | 64 |
York University
| 2 years |
| Leslie Aaron Grober | M | - |
York University
| 4 years |
| David Hunter | M | 57 |
York University
| 4 years |
| Sharon Ranson | F | 66 |
York University
| 2 years |
| David Lonsdale | M | - |
The University of Nottingham
| 3 years |
| Emanuele Bergagnini | M | - |
York University
| 5 years |
| Andy Davidson | M | - |
The University of Nottingham
| 3 years |
| Doug Clark | M | - |
York University
| 5 years |
| Stephen Plummer | M | - |
York University
| 2 years |
| Nirvaan Meharchand | M | 58 |
York University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 75 | 75.76% |
| United Kingdom | 24 | 24.24% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stephen Franklin
- Personal Network
